Cadila Healthcare lost 2.3% to Rs 870 at 10:23 IST on BSE, with the stock sliding on profit booking after recent rally.
Meanwhile, the S&P BSE Sensex was up 52.33 points or 0.25% at 20,765.70.
On BSE, so far 22,000 shares were traded in the counter as against average daily volume of 29,314 shares in the past one quarter.
The stock hit a high of Rs 899.70 and a low of Rs 862 so far during the day. The stock had hit a 52-week low of Rs 631 on 20 August 2013. The stock had hit a 52-week high of Rs 924.60 on 22 February 2013.
The stock had outperformed the market over the past one month till 9 January 2014, advancing 21.31% compared with the Sensex's 2.87% fall. The scrip had also outperformed the market in past one quarter, jumping 31.92% as against Sensex's 2.29% rise.
The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Rs 5.
Also Read
Shares of Cadila Healthcare had rallied 14.19% in four trading sessions to settle at Rs 890.45 on Thursday, 9 January 2014, from a recent low of Rs 779.75 on 3 January 2014.
Cadila Healthcare at the fag end of trading hours on Thursday, 9 January 2014 said it has received final approval from the US Food and Drug Administration (USFDA) to market Sirolimus Tablets 0.5 mg in the United States with 180 days of marketing exclusivity. The stock had jumped 5.29% to settle at Rs 890.45 on Thursday, 9 January 2014.
As per IMS data in 2013, the total market for Sirolimus was approximately $203.8 million in the United States.
Cadila Healthcare also said that the company has received approval from USFDA for Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg. Duloxetine had US sales of about $5.5 billion in 2013.
While Sirolimus tables are immunossuppresssant drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.
The Cadila group now has 86 approvals and has so far filed 216 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04, the company said.
Cadila Healthcare's consolidated net profit surged 93.8% to Rs 183.37 crore on 12.3% growth in net sales to Rs 1698.25 crore in Q2 September 2013 over Q2 September 2012.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News